Table 2.
Reirradiation outcomes of IMRT
| Author (institute) | Year | n | Patients characteristics [pre-RT dose/interval] | Treatment (no. of patients) | Radiotherapy | Outcome | Adverse reaction |
|---|---|---|---|---|---|---|---|
| Sulman et al. [33] (MDAC) | 2009 | 74 | Rec | CTX (26) | 60 Gy | 2-yr OS (58%)/2-yr LRC (64%) | Severe 15 (20%) |
| [60 Gy/46M] | Platinum based | Death 1 (unknown cause) | |||||
| Popovtzer et al. [42] (Michigan University) | 2009 | 66 | Rec/2nd | HfxRT ± CTX | 68 Gy, 1.25 Gy bid × 6 weeks | 2y OS (40%)/2-yr LCR (27%) | Acute G3 26, G4 11 |
| [64 Gy/37M] | CTX (47) (cisplatin etc.) | Late G3 19 (29%) | |||||
| Duprez et al. [36] (Belgium) | 2009 | 84 | Rec/2nd | OP (19) | 69 Gy | 2-yr OS (35%)/2-yr LCR (48%) | Acute G3 26 (31%) |
| [61 Gy/49.5M] | CTX (17) (cisplatin etc.) | Late G3 11 (14%) | |||||
| Biagioli (Miami) | 2007 | 41 | Rec | CTX | 60 Gy/30 fx, each other week | RR (76%)/2-yr OS (48.7%) | Acute G3 (32%) |
| [60 Gy/25M] | Cisplatin or carboplatin | Late 6 | |||||
| Lee et al. [22] (MSK) | 2007 | 105 | Rec | IMRT (74), non-IMRT (31) | 59.4 Gy | RR (50%)/2-yr OS (37%)/2-yr LRC (42%) | Acute G3-4 (23%) |
| [62 Gy/38M] | 71% CTX | Late G3-4 (15%; severe 11%) | |||||
| Sher (Dana–Farber) | 2010 | 35 | Rec | Cisplatin or cetuximab | 67.56 Gy (1.8–2.0 Gy daily) | LRC (67%), 2-yr OS (49%) | Late G3-4 (46%), Lethal (11%) |
| [30M] | CTX | ||||||
| Kharofa et al. [23] (Wisconsin) | 2012 | 38 | Rec | Carboplatin + paclitaxel | 68 Gy (2.0 Gy daily) | 2-yr OS (49%) | Late G3-4 (16%), IMRT (7%), |
| [28M] | Lethal (0%) |
IMRT, intensity-modulation radiation therapy; RT, radiation therapy; Rec, recurrence; M, months; CTX, chemotherapy; OS, overall survival; LRC, locoregional control; HfxRT, hyperfractionated radiation therapy; bid, twice a day; G, grade; MDAC, MD Anderson Cancer Center; MSK, Memorial Sloan-Kettering Cancer Center.